PVLA Stock — Palvella Therapeutics, Inc.: Metrics

Market overview

2 metrics

Share price

$150.55

Market cap

$2.17B

Price action

19 metrics

Price change (1W)

+1.6%

Price change (30D)

+6.9%

Price change (3M)

+43.8%

Price change (6M)

+14.5%

Price change (YTD)

+43.8%

Price change (1Y)

+178.0%

Trailing year

Price change (5Y)

—

52-week high

$157.77

52-week low

$52.71

Change from 52-week high

-4.6%

Change from 52-week low

+185.6%

Annualized volatility

83.7%

Beta

1.7

RSI (14D)

52.2

Price vs SMA 50

+2.6%

Price vs SMA 200

+27.8%

Avg volume (3M)

254,341

Relative volume

0.5

Average dollar volume

$34.71M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

14.41M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

1,604.4×

reciprocal yield 0.1%

P / book

10.0

reciprocal yield 10.0%

FCF yield

—

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-2.8%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-08-04

Profitability

9 metrics

Gross margin

—

Operating margin

-27.7%

Trailing 12 months

Net margin

43.7%

Gross profit (TTM)

—

Operating profit (TTM)

−$57.74M

Net income (TTM)

−$61.70M

Trailing 12 months

Diluted EPS (TTM)

$-4.83

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$-0.08

Growth

11 metrics

Revenue growth YoY

-100.0%

Year over year

Net income growth YoY

—

Revenue (TTM)

$1.35M

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+29.9%

Year over year · more shares

Revenue CAGR (3Y)

+13.4%

Revenue CAGR (5Y)

+8.0%

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-28.4%

Return on assets

-24.3%

Debt / equity

—

Current ratio

21.2

EBITDA (TTM)

—

Free cash flow (TTM)

—

Quick ratio

21.2

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$250.58M

Latest balance sheet

Cash & equivalents

$187.80M

Total assets

$253.51M

Total debt

—

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$36.51M

Capital expenditures (TTM)

—

R&D (TTM)

$35.46M

SG&A (TTM)

—

Stock compensation (TTM)

$12.40M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

199

13F filer change QoQ

+16

Institutional ownership

101.1%

Short interest

3 metrics

Short interest

14.9%

Latest settlement · 12.8 days to cover

Days to cover

12.8d

Short-squeeze score

77 / 100

Insider activity

2 metrics

Net insider buying (90D)

−$1.77M

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

PVLA · Palvella Therapeutics, Inc.

PVLA metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search